<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660062</url>
  </required_header>
  <id_info>
    <org_study_id>DUAG-7</org_study_id>
    <nct_id>NCT00660062</nct_id>
  </id_info>
  <brief_title>Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)</brief_title>
  <acronym>DUAG-7</acronym>
  <official_title>Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillerod Hospital, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the relapse preventing efficacy of&#xD;
      escitalopram in a dose range and nortriptylin in a single dose in patients having been&#xD;
      treated successfully with a course of electroconvulsive treatment (ECT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study records severity of depression and relapse in patients treated for a major&#xD;
      depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of&#xD;
      ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg,&#xD;
      20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and&#xD;
      secondary outcome measure is tolerability.&#xD;
&#xD;
      The study is a multicenter trial within Denmark.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow inclusion&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton depression rating scale</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drop out due to side-effects of drugs</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram 10 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 10 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram 20 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escitalopram 30 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram 30 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nortriptylin 100 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nortriptylin 100 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10 mg daily</description>
    <arm_group_label>Escitalopram 10 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>20 mg daily dosage</description>
    <arm_group_label>Escitalopram 20 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>30 mg daily dosage</description>
    <arm_group_label>escitalopram 30 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nortriptyline</intervention_name>
    <description>100 mg daily dosage</description>
    <arm_group_label>Nortriptylin 100 mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Remission from a major depressive episode after ECT treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suicidality (Hamilton item 3 score of 3 or more)&#xD;
&#xD;
          -  Symptoms mania (MAS score of 15 or more)&#xD;
&#xD;
          -  Duration of actual depressive episode more than 2 years&#xD;
&#xD;
          -  Compulsory measures of any kind&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Severe somatic illness&#xD;
&#xD;
          -  Pregnant or lactating subject&#xD;
&#xD;
          -  Known clinical relevant malabsorption.&#xD;
&#xD;
          -  Epilepsia&#xD;
&#xD;
          -  Clinically substantial cognitive deterioration due to ECT treatment&#xD;
&#xD;
          -  schizophrenia, schizopreniform or schizo-affective disorder&#xD;
&#xD;
          -  Bipolar I, Bipolar II eller&#xD;
&#xD;
          -  Rapid cycling bipolar disorder&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Early relapse (less than 2 month) after ECT&#xD;
&#xD;
          -  Inadequate contraception&#xD;
&#xD;
          -  Known intolerance to any of the used study medications&#xD;
&#xD;
          -  Myocardial infarction in the last 6 month&#xD;
&#xD;
          -  Clinical important liver disease&#xD;
&#xD;
          -  Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other&#xD;
             clinical important cardiac disease&#xD;
&#xD;
          -  Treatment with a MAO-inhibitor&#xD;
&#xD;
          -  Treatment with norepinephrine or epinephrine&#xD;
&#xD;
          -  Known hyperthyroidism or treatment with thyroid hormones&#xD;
&#xD;
          -  Known ortostatic hypertension.&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Known hereditary galactoseintolerance, Lapp Lactase deficiency) or&#xD;
             gluco-se/galactosemalabsorption.&#xD;
&#xD;
          -  Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine,&#xD;
             dopamine, levodopa, phenylephrine.&#xD;
&#xD;
          -  Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines,&#xD;
             atropine, biperiden,&#xD;
&#xD;
          -  Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine,&#xD;
             antihistamines, terfenadine og sotalole&#xD;
&#xD;
          -  Ongoing treatment with fluconazole or terbinafine&#xD;
&#xD;
          -  Ongoing treatment with mefloquin.&#xD;
&#xD;
          -  Known intolerance to escitalopram&#xD;
&#xD;
          -  Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Martiny, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mental Health Center Copenhagen Department O</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mental Health Centre Copenhagen Department O</name>
      <address>
        <city>Copenhagenl</city>
        <zip>2100 Ã˜</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.duag.dk</url>
    <description>homepage for the DUAG organization</description>
  </link>
  <reference>
    <citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.</citation>
    <PMID>11255384</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>December 7, 2014</last_update_submitted>
  <last_update_submitted_qc>December 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hillerod Hospital, Denmark</investigator_affiliation>
    <investigator_full_name>Klaus Martiny</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Major depression</keyword>
  <keyword>relapse prevention</keyword>
  <keyword>ECT</keyword>
  <keyword>escitalopram</keyword>
  <keyword>nortriptyline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

